शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
The note is the current scenario (Base). Download PDF renders this page on the server, fonts and colours exact; Print uses the browser.
Model Note · MANGALAM DRUG & CHEM LTD · 7 November 2026Page 1 of 2
Model Note
Prepared by the reader · not a MarketPing document
MANGALAM DRUG & CHEM LTD
Discounted cash flow · base FY26

MANGALAM DRUG & CHEM LTD

Value per share, this model₹(234)
CMP, 6 Nov 2026₹28.87
Difference(909.6)%
Growth the CMP implies—

This note states the assumptions and the arithmetic of one model of MANGALAM DRUG & CHEM LTD, built on its filed FY26 consolidated statements. The value is the outcome of the assumptions below and nothing else; it is not a fair value, a target or a recommendation.

Assumptions

InputThis modelFiled reference
Revenue growth, 5 years-5% a yearFY26 (27.1)% · 5-yr CAGR —%
EBITDA margin-6.4%FY26 (6.4)% · 5-yr average 3.2%
Depreciation · capex, % of revenue7.9% · 5.1%, fading to 1.2× depreciationFY26 7.9% · 5.1%
Working capital, % of added revenue · tax28.9% · 25.17%106 working-capital days · effective 25.2%
Discount rate11.00%1-yr beta 0.61
After FY315% flat · mid-year discounting—
Net debt · non-controlling interest · non-operating investments₹105 · ₹0 · ₹0 crFY26 net debt ₹105 cr
Shares1.58 crore1.58 crore today
Source: SEBI results XBRL as filed with BSE/NSE, exchange prices; the reader's assumptions.

Projected cash flow to the firm

₹ croreFY26FY27FY28FY29FY30FY31
Revenue232221209199189180
growth %(27.1)(5.0)(5.0)(5.0)(5.0)(5.0)
EBITDA(15)(14)(13)(13)(12)(11)
Depreciation(18)(17)(17)(16)(15)(14)
NOPAT(25)(24)(22)(21)(20)(19)
less capex(12)(11)(13)(15)(16)(17)
less working-capital build—33333
Free cash flow to firm—(14)(16)(17)(18)(19)
Present value(13)(13)(13)(13)(12)
Source: the model; base year as filed.
Every figure is the reader's model over filed numbers · No rating, target or fair value is expressedmarketping.in
Model Note · MANGALAM DRUG & CHEM LTD · 7 November 2026Page 2 of 2

From enterprise to equity

PV of the 5 explicit years(65)
PV of the terminal value (—% of EV)(201)
Enterprise value(265)
less net debt(105)
less non-controlling interest0
add non-operating investments0
Equity value(370)
÷ 1.58 crore shares₹(234)
Source: the model.

Sensitivity, ₹ per share

WACC ↓ · terminal growth →4.0%4.5%5.0%5.5%6.0%
10.0%(239)(252)(267)(286)(309)
10.5%(226)(236)(249)(264)(282)
11.0%(215)(223)(234)(246)(261)
11.5%(205)(212)(221)(231)(243)
12.0%(196)(203)(210)(219)(228)
Source: the model; n/a where terminal growth reaches the discount rate.

Statement

This note is the reader's own model over publicly filed information: SEBI results XBRL filed with BSE and NSE and exchange price data, assembled by MarketPing software; every assumption above is the reader's. It contains no research recommendation, no price target and no opinion by MarketPing on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Historical per-share figures are on the current share count. Where a figure is unavailable the table shows a dash rather than an estimate. Nothing here constitutes investment advice, an offer or a solicitation.

Every figure is the reader's model over filed numbers · No rating, target or fair value is expressedmarketping.in